Log In
BCIQ
Print this Print this
 

Pralia, Prolia, Ranmark, Xgeva, denosumab (AMG 162)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb targeting receptor activator of NF-kappa B ligand (RANKL; TNFSF11)
Molecular Target Receptor activator of NF-kappa B ligand (RANKL) (TNFSF11)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$120.0M

0

0


 Deals Details
Get a free BioCentury trial today